Fairfax, VA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)The Side-Out Foundation, founded in 2005, is a community nonprofit in the Education sector that reported $1.5M in total revenue in fiscal year 2024. Revenue grew 9% year-over-year, indicating healthy expansion. Expenses of $1.6M exceeded revenue, resulting in a 11% operating deficit.
Making breast cancer a manageable disease (similar to diabetes) takes an organization with extraordinary vision & cutting-edge tactics. The Side-Out Foundation is a 501(c)(3) non-profit organization, founded in 2004 by Richard and Bryant Dunetz, to empower a new generation of advocates, make significant and identifiable impact on the way breast cancer is treated, and give those living with metastatic breast cancer (MBC) more tomorrows.Since its inception, the foundation has (I) built educational and community-driven programs focused on teaching advocacy to the next generation of changemakers, equipping them with skills and tools to support Side-Out's mission, as well as any cause they wish to connect to in their future; (II) forged groundbreaking collaborations with prestigious research teams, hospitals, and research centers nationwide and; (III) leveraged new technologies to improve, alter cancer trajectories, and constantly challenge the foundation of cancer care.
During the 20242025 fiscal year we achieved the following research objectives.1. Publication in the British Journal of Cancer. Our manuscript, "Functional activation of the AKTmTOR signalling axis in...
During the 20242025 fiscal year we achieved the following research objectives.1. Publication in the British Journal of Cancer. Our manuscript, "Functional activation of the AKTmTOR signalling axis in a real-world metastatic breast cancer cohort" by Rasad D, Baldelli E, Blais EM, Davis J, El Gazzah E, Mueller C, Gomeiz A, Ibrahim A, Newrekar AV, Corgiat BA, Dunetz R, Petricoin III EF, Wei Q, and Pierobon M, was published in the British Journal of Cancer (Br J Cancer. 2024 Nov;131(9):1543-1554). This study analyzed a real-world cohort of 171 metastatic breast cancer patients who underwent multi-omic profiling through Perthera. The primary objective was to characterize metastatic lesions from a genomic perspective and compare them with historical cohorts of primary tumors, with a particular focus on how genetic alterations in the AKTmTOR pathway translate into phenotypic changes at the protein level. The findings represent an important step forward for precision medicine and demonstrate the superiority of multi-omic approaches in identifying patients who may respond to inhibitors targeting the AKT-mTOR pathway. In addition, the study further validated that increased activation of AKT downstream substrates is associated with response to CDK4/6 inhibitor therapy, consistent with observations from the Side Out 3 clinical trial (NCT03195192).2. Discovery of a novel protein-protein interaction with therapeutic relevance. We identified a previously uncharacterized protein-protein interaction that represents a new druggable axis and a potential predictor of response to CDK4/6 inhibitors combined with endocrine therapy in metastatic breast cancer. This discovery emerged from preclinical studies conducted at George Mason University and resulted in the submission of a provisional patent application for the development of a novel diagnostic test to guide patient allocation to targeted treatments.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $1,478,970 | $1,361,469 | +0.1% |
| Expenses | $1,642,957 | $1,188,997 | +0.4% |
| Net Income | $-163,987 | $172,472 | -2.0% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Rick Dunetz | Chief Vision Officer | 40.00 |
Officer
Director
|
$110,434 | $5,469 | $115,903 |
| Gary Thompson | Board chair | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Stephanie Reffey | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Sharon Dingman | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Ellen Dempsey | Executive Director | 40.00 |
Officer
|
$149,908 | $6,663 | $156,571 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $1,478,970 | $1,642,957 | $2,106,993 | $-163,987 |
| 2024 | $1,361,469 | $1,188,997 | $2,115,644 | $172,472 |
| 2023 | $1,232,509 | $1,349,545 | $2,116,765 | $-117,036 |
| 2022 | $1,141,094 | $1,269,964 | $1,966,126 | $-128,870 |
| 2021 | $398,419 | $1,146,091 | $2,026,191 | $-747,672 |
| 2020 | $1,396,295 | $1,507,039 | $2,913,522 | $-110,744 |
| 2019 | $1,344,877 | $1,349,162 | $3,118,086 | $-4,285 |
Compare The Side-Out Foundation with other nonprofits in Virginia and across the country.